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Background: Responsiveness to erythropoiesis-stimulating agents (ESAs) varies widely among dialysis patients. ESA
resistance has been associated with mortality in hemodialysis (HD) patients, but in peritoneal dialysis (PD) patients
data is limited. Therefore we assessed the relation between ESA resistance in both HD and PD patients.
Methods: NECOSAD is a Dutch multi-center prospective cohort study of incident dialysis patients who started
dialysis between January 1997 and January 2007. ESA resistance was defined as hemoglobin level < 11 g/dL with an
above median ESA dose (i.e. 8,000 units/week in HD and 4,000 units/week in PD patients). Unadjusted and adjusted
Cox regression analysis for all-cause 5-year mortality was performed for HD and PD patients separately.
Results: 1013 HD and 461 PD patients were included in the analysis. ESA resistant HD patients had an adjusted
hazard ratio of 1.37 (95% CI 1.04-1.80) and ESA resistant PD patients had an adjusted hazard ratio of 2.41 (1.27-4.57)
as compared to patients with a good response.
Conclusions: ESA resistance, as defined by categories of ESA and Hb, is associated with increased mortality in both
HD and PD patients. The effect of ESA resistance, ESA dose and hemoglobin are closely related and the exact
mechanism remains unclear. Our results strengthen the need to investigate and treat causes of ESA resistance not
only in HD, but also in PD patients.
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Anemia is a common complication of end stage renal
disease and has been associated with increased mortality
in dialysis patients [1]. Therefore about 90% of dialysis
patients receive erythropoiesis-stimulating agents (ESAs)
[2]. ESAs are prescribed and titrated according to the
change in hemoglobin (Hb) level, but responsiveness to
ESAs varies widely among dialysis patients [3]. The pa-
tients with a reduced hematopoietic response to ESAs
are called ESA resistant or hyporesponsive [4,5].
Different definitions are being used to define ESA
resistance, based on Hb change per ESA dose increase,
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reproduction in any medium, provided the orindex (ERI) [6-8]. The KDOQI guideline describes ESA
resistance as an inappropriately low Hb for the admi-
nistered ESA dose, which includes patients who fail to
achieve the target Hb of 11 g/dL while treated with high
ESA doses [9].
ESA resistance has been associated with a 1.4- to a more
than 2-fold increased mortality rate [10-13]. This associ-
ation has predominantly been studied in hemodialysis
(HD) patients, whereas 20 to 30% of dialysis patients in
the Netherlands are treated with peritoneal dialysis (PD)
[14]. Only one previous US study examined the associ-
ation between ESA resistance and mortality separately
for HD and PD patients, in which ESA resistance was
associated with higher mortality rates in HD patients.
However, this was not confirmed in PD patients [15].
Only PD patients treated with excessively high ESA doses
had a higher mortality rate. To verify the differentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Suttorp et al. BMC Nephrology 2013, 14:200 Page 2 of 10
http://www.biomedcentral.com/1471-2369/14/200association between ESA resistance and mortality in HD
and PD patients, these results need replication, especially
in a European patient population with lower ESA doses.
Therefore, we aimed to assess the association between
ESA resistance and mortality during 5 years of follow-
up in both HD and PD patients. In a prospective cohort
of incident dialysis patients in the Netherlands, we iden-
tified ESA resistant patients by categories of ESA dose
and Hb level.Methods
Study design and participants
The Netherlands Cooperative Study on the Adequacy of
Dialysis (NECOSAD-II) is a prospective cohort study in
which incident dialysis patients from 38 dialysis centers
throughout the Netherlands were enrolled between January
1997 and January 2007. Patients were eligible if they started
dialysis for the first time and were 18 years or older. All pa-
tients gave written informed consent before inclusion. Base-
line was defined as 180 days after start of dialysis to account
for the first period with therapy switches and deaths prob-
ably due to health status before start of dialysis. Further-
more, at this time point 92% of the ESA using dialysis
patients were treated with ESAs for at least 3 months and
ESA dose and Hb can be considered in a stable phase.
The NECOSAD study was approved by the medical ethical
committees of all participating centers (Maasstad Hospital
Rotterdam, Deventer Hospital Deventer, Sint Lucas Andreas
Hospital Amsterdam, Academic Medical Center Amsterdam,
Maxima Medical Center Veldhoven, Catharina Hospital
Eindhoven, Medical Center Haaglanden Den Haag, Uni-
versity Medical Center Groningen, Kennemer Gasthuis
Haarlem, Atrium Medical Center Heerlen, Medical Center
Leeuwarden, Leiden University Medical Center Leiden,
Elisabeth Hospital Tilburg, University Medical Center
Utrecht, Antonius Hospital Nieuwegein, Hospital
Gelderse Vallei Ede, Haga Hospital Leyenburg Den Haag,
Academic Hospital Maastricht, Jeroen Bosch Hospital Den
Bosch, Medisch Spectrum Twente Enschede, Albert
Schweitzer Hospital Dordrecht, Alysis Zorggroep Rijnstate
Hospital Arnhem, Dianet Dialysis Center Lunetten
Utrecht, Canisius Wilhelmina Hospital Nijmegen, Vie Curi
Medical Center Venlo, Leveste Scheper Hospital Emmen,
Dianet Dialysis Center Holendrecht Amsterdam, Haga
Hospital Rode Kruis Den Haag, Rijnland Hospital
Leiderdorp, Admiraal de Ruyter Hospital Goes, Medical
Center Alkmaar, Laurentius Hospital Roermond, Dialysis
Center ’t Gooi Hilversum, Groene Hart Hospital Gouda,
Westfries Gasthuis Hoorn, Tergooi Hospitals Hilversum,
Martini Hospital Groningen, Zaans Medical Center
Zaandam). For the present analysis, all patients treated
with ESAs and with data on Hb and ESA dose at 6 months
after start of dialysis were included.Patient characteristics
Patient characteristics were collected at start of dialysis,
including age, gender and primary kidney disease. Pri-
mary kidney disease was classified according to the
European Renal Association- European Dialysis and
Transplant Association (ERA-EDTA) codes [16]. Data
on weight, comorbidity and laboratory parameters were
collected six months after start of dialysis. Comorbid
conditions were classified by the nephrologist. Cardio-
vascular disease consisted of angina pectoris, myocardial
infarction, heart failure, stroke and claudication. Nutri-
tional status was measured by trained nurses with the 7-
point subjective global assessment (SGA) [17]. A score
of 1 or 2 was classified as severely malnourished and 6
or 7 as well-nourished. For HD patients, blood samples
were taken before the dialysis session. Hb, albumin, fer-
ritin, parathyroid hormone (PTH), creatinine, urea and
C-reactive protein (CRP) were measured in serum. Urea
and creatinine were also determined in urine. Residual
glomerular filtration rate (rGFR) was calculated as the
mean of creatinine and urea clearance corrected for
body surface area (mL/min per 1.73 m2). Dialysis dose
was expressed as total Kt/V urea per week and calcu-
lated according to Watson et al. [18].
ESA resistance
ESA dose was registered in units per week at baseline.
Darbepoetin dose in micrograms was converted to units
by multiplying with 200. Patients were divided into four
categories based on target Hb and median ESA dose.
Patients were considered ESA resistant if they failed to
reach target Hb (11 g/dL) [9,19] while treated with an
above median ESA dose (8,000 units/week for HD and
4,000 units/week for PD patients). Good ESA responders
reached target Hb with a median or lower ESA dose.
Outcome definition
The endpoint was 5-year mortality. Cause of death was
classified according to the ERA-EDTA codes [19]. Cardio-
vascular mortality was defined as death due to myocardial
ischemia and infarction, hyperkalemia, hypokalemia,
cardiac arrest, cardiac failure, fluid overload, cerebro-
vascular accident, pulmonary embolism, hemorrhage
from ruptured aneurysm, mesenteric infarction and cause
of death uncertain.
Statistical analyses
Continuous variables are presented as mean with stand-
ard deviation (SD) or median with interquartile range
(IQR), depending on the normality of the data. Categor-
ical variables are presented as percentages. Survival time
was calculated as time between baseline and date of
death or censoring (i.e. renal transplantation, recovery of
renal function, withdrawal of participation or end of
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modality. Mortality rates were calculated and Cox re-
gression analysis was used to calculate hazard ratios
(HR) with 95% confidence interval (CI) for 5-year all-
cause mortality. Patients with a good ESA response
served as the reference category. The proportional ha-
zards assumption was verified by plotting the log minus
log plots. Analyses were adjusted for a priori defined
confounders age, sex, primary kidney disease, cardiovas-
cular disease, malignancy, diabetes mellitus, Kt/Vurea,
rGFR, albumin, ferritin, PTH and CRP. Missings were
less than 3%, except for PTH (4.6%), albumin (5.3%),
SGA (15.6%), rGFR (22.0%), Kt/Vurea (23.4%) and CRP
(51.2%). Missing data were imputed with standard
multiple imputation techniques with 10 repetitions,
which are based on the Markov Chain Monte Carlo
(MCMC) method [20]. Results for cardiovascular and
non-cardiovascular causes of death were also analysed
separately.Sensitivity analysis
To explore dose dependent effects of ESA and Hb on
mortality, analysis with more categories of ESA and Hb
were conducted. Furthermore, ERI was calculated by
dividing the weekly ESA dose per kilogram by Hb
(weekly units/kg/Hb). Patients were grouped into quar-
tiles of ERI, in which the highest ERI quartile corre-
sponds with ESA resistance. Cox regression analyses
were performed with the lowest ERI quartile as a refer-
ence. Last, since CRP was missing in a high percentage
of patients, we also performed our analyses only in those
patients with a measured CRP and without adjustment
for CRP, to further validate our results. All analyses were
performed with SPSS statistical software version 20.0.Results
A total of 2051 patients were enrolled and after 6 months
1791 patients were still on dialysis, 34 received kidney
transplantation, 140 died, 19 experienced recovery of
renal function, 52 withdrew participation and 15 patients
left for other reasons. Of the 1791 patients 1528 were
treated with ESA. Data on Hb and ESA dose were avail-
able in 1474 patients (1013 HD and 461 PD) and those
patients were included in the present analysis. Median
ESA dose was 8,000 units/week in HD and 4,000 units/week
in PD patients.
In Table 1 and Table 2 baseline characteristics of
HD and PD patients are shown by ESA and Hb ca-
tegories. PD patients were younger than HD patients
and rGFR was higher in PD patients. Overall, ESA re-
sistant patients had lower rGFR, lower albumin levels
and higher ferritin levels. PD patients with higher ESA
doses had more comorbidities and higher CRP ingeneral, while for HD the comorbidities and higher
CRP were more pronounced in ESA resistant patients.
Outcomes
A total of 572 patients died during 5 years of follow-up.
The observed rates of all-cause mortality are listed in
Table 3. In both HD and PD patients the mortality rate
was around twice as high in the ESA resistant group as
compared to the good responders. In PD the mortality
rate in patients with a high ESA dose but with a good
Hb response was somewhat higher than in the ESA re-
sistant patients. The highest all-cause mortality was
observed in ESA resistant HD patients (243 deaths per
1,000 person years).
ESA resistance and mortality
The unadjusted HR for ESA resistant HD patients as
compared to good responders according to ESA and Hb
categories was 1.72 (95% CI 1.34-2.20) as shown in
Table 4. After adjustment for general characteristics and
comorbidities ESA resistance was still associated with an
almost 2 fold increased all-cause mortality rate. Full ad-
justment downgraded the HR to 1.37 (95% CI 1.04-1.80).
In PD patients both groups with high ESA doses were
associated with increased mortality in crude analysis, ir-
respective of Hb. After full adjustment the HR in ESA
resistant PD patients was 2.41 (95% CI 1.27-4.57). The
higher mortality rate in PD patients with high ESA dose
but with good Hb attenuated mainly after adjustment
for co-morbidities, resulting in a fully adjusted HR of
1.56 (95% CI 0.96-2.51).
Causes of death
In HD patients the relation of ESA resistance with non-
cardiovascular mortality was more evident than with cardio-
vascular mortality (Figure 1). The HR for non-cardiovascular
mortality was 1.82 (95% CI 1.25-2.65) and cardiovascular
mortality was 1.04 (95% CI 0.70-1.56). In PD patients ESA
resistance was associated with both causes of death, al-
though the association with cardiovascular mortality was
more pronounced and statistically significant. The ad-
justed hazard ratio for cardiovascular mortality was 3.11
(95% CI 1.35-7.18) and for non-cardiovascular mortality
1.98 (95% CI 0.76-5.17). Analyses based on ERI quartiles
did not materially change these results.
Sensitivity analyses
To explore ESA dose dependency, analysis was
performed by creating 8 categories of ESA and Hb in
HD patients (Figure 2). The number of patients
prevented us from creating more categories and
performing this analysis in PD patients. Although confi-
dence intervals were wide, point estimate for mortality
Table 1 Baseline characteristics of HD patients
HD patients ESA ≤8,000 (units/week) ESA >8,000 (units/week)
Hb ≥11 (g/dl) Hb <11 (g/dl) Hb ≥11 (g/dl) Hb <11 (g/dl)
Number 380 264 158 211
Age (years) 64.5 (13.2) 64.1 (14.4) 64.9 (13.7) 64.2 (12.8)
Sex (%) men 60.4 56.1 65.0 56.4
Weight (kg) 70.6 (12.4) 72.0 (14.3) 74.1 (14.9) 73.6 (14.8)
ESA dose (units/week) 6,000 (4,000-8,000) 6,000 (4,000-8,000) 12,000 (10,000-16,000) 12,000 (12,000-18,000)
ERI (units/week/kg/Hb) 6.5 (2.9) 7.9 (3.4) 16.0 (6.3) 22.3 (13.5)
Primary kidney disease (%)
- Diabetes mellitus 10.6 17.4 16.5 15.6
- Glomerulonephritis 11.1 7.6 8.2 8.5
- Renal vascular disease 22.2 21.6 12.7 19.0
- Other 56.2 53.4 62.7 56.9
Comorbidity (%)
- Diabetes mellitus 17.1 20.8 27.2 24.2
- Malignancy 7.4 9.8 11.4 18.5
- Cardiovascular disease 39.2 41.3 32.9 40.8
Weekly Kt/V urea (Watson) 3.7 (0.9) 3.5 (0.9) 3.7 (0.8) 3.7 (1.0)
rGFR (ml/min/1.73 m2) 2.9 (1.5-4.4) 2.3 (0.8-3.8) 2.1 (0.8-4.2) 1.5 (0.4-3.2)
Nutritional status (SGA) (%)
- Severely malnourished 0.3 2.2 0.8 5.4
- Mild-moderate 19.1 25.4 27.1 37.3
- Well-nourished 80.6 72.4 72.0 57.2
Laboratory values
- Hemoglobin (g/dl) 12.1 (11.6-12.7) 10.3 (9.5-10.6) 12.1 (11.6-12.8) 9.8 (9.2-10.5)
- Albumin (g/l) 37.5 (4.5) 36.0 (4.9) 35.6 (4.5) 34.1 (6.0)
- Ferritin (μg/l) 190 (104–380) 175 (94–379) 229 (121–434) 257 (118–511)
- PTH (pmol/l) 12.1 (5.5-23.8) 10.6 (4.7-23.9) 16.3 (6.4-33.7) 10.0 (3.2-23.4)
- CRP (mg/l) 6.0 (3.0-12.0) 6.0 (3.0-15.0) 9.0 (3.0-17.0) 14.0 (6.0-34.5)
Values are presented as mean (SD), median (IQR) or percentage.
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highest ESA dose, representing ESA resistant patients. A
dose dependent effect of ESA was not definite. In HD
patients with a Hb ≥11 g/dL the HR did not further in-
crease in patients with the highest ESA dose. Also, al-
though patients with a low Hb and relatively high ESA
doses had increasing mortality rates, the patients with
the lowest ESA dose did not show the lowest mortality
rate.
In addition, Cox regression analyses were performed
with ESA resistance defined as the upper quartile of ERI
(Table 5). In HD patients results were in line with the
results based on ESA and Hb categories. A dose re-
sponse relation was observed, although less pronounced
after full adjustment, and the mortality rate in the
highest ERI quartile remained increased (HR of 1.34
(1.00-1.80)). In PD patients the association between ERIand mortality became more J-shaped. Patients in the
lowest ERI quartile had a higher mortality rate than in
the middle quartiles. In quartile 2 to 4 mortality rate
rose gradually with a slightly increased mortality rate in
the ESA resistant patients compared to the first quartile
(1.18 (95% CI 0.68-2.07)).
Because of the high percentage of imputed CRP data,
our analysis was also repeated only in those patients
with known CRP value and without additional adjust-
ment for CRP in all patients. With both analyses our re-
sults did not materially change (data not shown).
Discussion
In this prospective study of 1474 incident dialysis pa-
tients, we found that ESA resistance, defined according
to categories of ESA and Hb, was associated with an in-
creased 5-year mortality rate as compared to patients
Table 2 Baseline characteristics of PD patients
PD patients ESA ≤4,000 (units/week) ESA >4,000 (units/week)
Hb ≥11 (g/dl) Hb <11 (g/dl) Hb ≥11 (g/dl) Hb <11 (g/dl)
Number 204 91 113 53
Age (years) 52.0 (14.7) 50.6 (15.1) 57.9 (15.5) 49.8 (16.1)
Sex (%) men 64.2 65.9 73.2 60.4
Weight (kg) 73.1 (12.8) 73.5 (14.3) 77.8 (13.7) 77.9 (16.8)
ESA dose (units/week) 4,000 (2,000-4,000) 4,000 (2,000-4,000) 8,000 (6,000-8,000) 9,000 (8,000-12,000)
ERI (units/week/kg/Hb) 3.4 (1.4) 4.5 (1.8) 9.0 (4.4) 14.9 (8.5)
Primary kidney disease (%)
- Diabetes mellitus 10.8 19.8 17.0 13.2
- Glomerulonephritis 18.1 17.6 17.9 17.0
- Renal vascular disease 7.8 8.8 21.4 13.2
- Other 63.2 53.8 43.8 56.6
Comorbidity (%)
- Diabetes mellitus 13.2 19.8 23.9 15.1
- Malignancy 5.4 2.2 8.8 5.7
- Cardiovascular disease 19.6 17.6 31.9 20.8
Weekly Kt/V urea (Watson) 2.3 (0.6) 2.1 (0.4) 2.3 (0.6) 2.1 (0.5)
rGFR (ml/min/1.73 m2) 3.7 (2.0-5.6) 2.7 (1.0-3.8) 3.1 (1.2-5.1) 1.3 (0.5-3.3)
Nutritional status (SGA) (%)
- Severely malnourished 0.6 0.0 0.0 0.0
- Mild-moderate 13.4 24.7 15.6 22.7
- Well-nourished 86.0 75.3 84.4 77.3
Laboratory values
- Hemoglobin (g/dl) 12.4 (11.8-13.3) 9.7 (10.3-10.8) 12.4 (11.7-13.2) 10.0 (9.5-10.8)
- Albumin (g/l) 37.4 (4.7) 35.4 (6.0) 36.0 (5.5) 34.0 (6.1)
- Ferritin (μg/l) 138 (63–232) 186 (81–294) 99 (51–180) 218 (114–479)
- PTH (pmol/l) 11.6 (4.6-23.8) 10.8 (3.6-31.3) 12.1 (4.3-28.9) 16.4 (3.5-25.0)
- CRP (mg/l) 4.0 (3.0-8.0) 4.0 (3.0-14.0) 9.5 (5.0-16.3) 7.0 (3.0-11.0)
Values are presented as mean (SD), median (IQR) or percentage.
Table 3 Mortality rates for all-cause mortality by ESA and Hb category
All-cause mortality
ESA (units/week) Hb (g/dl) Person years Death (n) Death rate/1,000 person years 95% CI
• HD patients
≤8,000 ≥11 1002 142 142 (120–167)
≤8,000 <11 661 121 183 (153–218)
>8,000 ≥11 358 68 190 (149–239)
>8,000 <11 469 114 243 (202–291)
• PD patients
≤4,000 ≥11 527 39 74 (53–100)
≤4,000 <11 218 25 115 (76–167)
>4,000 ≥11 247 45 182 (134–241)
>4,000 <11 109 18 166 (101–257)
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Table 4 Hazard ratios for all-cause mortality by ESA and Hb category
All-cause mortality
ESA (units/week) Hb (g/dL) Patients (n) Unadjusted HR Adjusted HR1 Adjusted HR2
• HD patients
≤8,000 ≥11 380 1 1 1
≤8,000 <11 264 1.29 (1.01-1.65) 1.33 (1.04-1.70) 1.18 (0.91-1.52)
>8,000 ≥11 158 1.35 (1.01-1.80) 1.52 (1.13-2.04) 1.28 (0.94-1.73)
>8,000 <11 211 1.72 (1.34-2.20) 1.91 (1.48-2.47) 1.37 (1.04-1.80)
• PD patients
≤4,000 ≥11 204 1 1 1
≤4,000 <11 91 1.59 (0.96-2.63) 1.94 (1.15-3.27) 1.56 (0.91-2.68)
>4,000 ≥11 113 2.55 (1.66-3.92) 1.89 (1.20-2.97) 1.56 (0.96-2.51)
>4,000 <11 53 2.34 (1.34-4.10) 3.18 (1.74-5.79) 2.41 (1.27-4.57)
Values are shown as hazard ratios (95% CI).
Categories are defined by a combination of ESA dose (below or from median) and Hb level (≥11 and <11 g/dL). The category with the high ESA dose and Hb <11
corresponds to ESA resistant patients and the category with the low ESA dose and Hb ≥11 corresponds to good ESA responders.
1 Adjusted for age, sex, weight, primary kidney disease, diabetes mellitus, malignancy, cardiovascular disease.
2 Additional adjusted for weekly Kt/V urea, rGFR, nutritional status, albumin, ferritin, PTH and CRP.
Figure 1 Hazard ratios for cardiovascular and non-cardiovascular mortality by ESA and Hb category. Values are shown as hazard ratios
(95% Confidence intervals). Adjusted for age, sex, weight, primary kidney disease, diabetes mellitus, malignancy, cardiovascular disease, weekly
Kt/V urea, rGFR, nutritional status, albumin, ferritin, PTH and CRP.
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Figure 2 All-cause mortality for 8 categories of ESA and Hb in HD patients. Values are shown as hazard ratios (95% Confidence intervals).
Adjusted for age, sex, weight, primary kidney disease, diabetes mellitus, malignancy, cardiovascular disease, weekly Kt/V urea, rGFR, nutritional
status, albumin, ferritin PTH and CRP.
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adjustment for potential confounders ESA resistance
was associated with a more than 2-fold increased mor-
tality rate in PD patients and a 1.4-fold increased mor-
tality rate in HD patients.
Data in PD patients are limited and only one previ-
ous US study, in which ESA dose was used to indicate
ESA resistance, examined the association between ESA
resistance and mortality in both PD and HD patients
[15]. In contrast to the analysis with ESA and Hb cat-
egories in our study, mortality rate was not increased
in ESA resistant PD patients with ESA doses up to
10,000 units/week. Only PD patients with ESA doses
exceeding 15,000 units/week, which is considerably
higher than in Dutch clinical practice, had a 28%
higher mortality rate. Reasons for the discrepant fin-
dings could be the dissimilarities in ESA prescribing
pattern between the two countries and differences inTable 5 Hazard ratios for all-cause mortality by ERI quartile











Values are shown as hazard ratios (95% CI).
Categories are defined by quartiles of ERI (weekly ESA dose/kg/Hb). The highest ER
quartile (quartile 1) corresponds to good ESA responders.
1 Adjusted for age, sex, weight, primary kidney disease, diabetes mellitus, malignan
2 Additional adjusted for weekly Kt/V urea, rGFR, nutritional status, albumin, ferritin,patient populations. The US study comprised prevalent
patients whereas our study included incident dialysis
patients. Prevalent PD patients represent healthier pa-
tients, because patients who already died or switched
to HD because of comorbidities are not taken into
account.
Our results in HD patients are in line with other stud-
ies relating ESA resistance with mortality. Studies using
change in hematocrit [10] or Hb [13] over time report
1.5- to more than 2-fold increased mortality in ESA
resistant HD patients. A large study in prevalent HD
patients from Japan also defined ESA resistance based
on categories of ESA and Hb [8]. They showed that
patients with an ESA dose from 6,000 units/week and
Hb below 10 g/dL had a HR of 1.94 for all-cause mor-
tality. An Italian study found a 62% increase in morta-
lity rate and 43% increase in cardiovascular events for
ESA resistant patients [7].All-cause mortality
Unadjusted HR Adjusted HR1 Adjusted HR2
1 1 1
1.08 (0.82-1.43) 1.16 (0.88-1.55) 1.11 (0.83-1.49)
1.33 (1.01-1.74) 1.28 (0.97-1.68) 1.07 (0.81-1.43)
1.81 (1.39-2.36) 1.85 (1.41-2.42) 1.34 (1.00-1.80)
1 1 1
0.63 (0.36-1.12) 0.45 (0.25-0.80) 0.45 (0.25-0.83)
1.24 (0.75-2.03) 0.95 (0.56-1.61) 0.77 (0.43-1.36)
1.72 (1.07-2.77) 1.46 (0.88-2.41) 1.18 (0.68-2.07)
I quartile (quartile 4) corresponds to ESA resistant patients and the lowest ERI
cy, cardiovascular disease.
PTH and CRP.
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have been used. In our analyses both ERI quartiles and
categories of ESA and Hb identified a group of patients
with the worst survival and results were comparable in
HD patients. In PD patients however, results with ERI
quartiles were less pronounced. In general, we believe
ERI is difficult to interpret because dose of ESA is not
normally distributed and the relation between ESA dose
and Hb is not linear. High ESA doses therefore result
in high ERI, irrespective of achieved Hb. For instance,
almost all HD patients in the highest ERI quartile in
our population are treated with an ESA dose ≥ 10,000
units/week. Hb levels, however, range from below 8 g/dL
to above 12 g/dL in these patients. ERI is therefore, to our
opinion, more a reflection of ESA dose than of ESA resist-
ance. Identifying ESA resistant patients by ESA dose and
Hb level seems more transparent and therefore better in-
terpretable and applicable in clinical practice.
The J-shaped relation in our sensitivity analyses be-
tween ERI quartiles and mortality in PD patients is due
to a higher mortality rate in the lowest ERI quartile as
compared to the middle ERI quartiles. Potential explana-
tions are speculative, but it might at least partly be
explained by the definition of the ERI quartiles. More
than half of the PD patients with an Hb ≥11 g/dL and a
low ESA dose, in our view patients with a good ESA re-
sponse, are not allocated to the lowest ERI quartile. As a
consequence, patients with a good response to ESA are
allocated to different ERI quartiles. Also, a quarter of PD
patients in the lowest ERI quartile did not reach target
Hb level of 11 g/dL and their response to ESA is there-
fore at least questionable.
In our study HD patients were treated with higher
ESA doses than PD patients, which is in agreement with
several other studies [15,21]. The lower ESA require-
ments could be due to a better preservation of residual
renal function in PD patients, which results in higher
endogenous erythropoietin production. rGFR was indeed
higher in PD patients, as was already reported in a previ-
ous analysis of this cohort [22]. Alternatively, it has also
been speculated that uremic toxins responsible for the
inhibition of erythropoiesis could be better removed by
a greater clearance of middle molecular weight sub-
stances by PD, resulting in a better hematopoietic re-
sponse [23]. Route of ESA administration could also
affect ESA dose and resistance. Various studies have
shown that ESA dose can be reduced when patients
switch from intravenous to subcutaneous administration,
although for darbepoetin with a longer half-life this is
not established [24]. In our cohort, route of ESA admin-
istration was documented in just 174 patients, in which
98% of PD and only 66% of HD patients received ESA
subcutaneously. Data on type of ESA was unavailable. Last,
HD patients experience more blood loss because offrequent blood testing, loss in the extracorporal circuit and
oozing from vascular access site. Blood loss can cause iron
deficiency, resulting in a decreased hematopoietic response
and therefore higher ESA requirements.
Indeed, the relatively low ferritin levels in HD and PD pa-
tients could indicate that part of the ESA resistance might
be caused by iron deficiency. However, ferritin was highest
in both ESA resistant HD and PD patients. This might indi-
cate that especially in these patients extra efforts were made
to adequately supplement the relative iron deficiency and
overcome ESA resistance. On the other hand, since ferritin
is also an acute phase protein, it could also reflect the higher
inflammation burden in these patients. Because further
specifications on iron status are lacking, a residual effect
of iron deficiency on ESA resistance cannot be excluded.
Over the last decade several papers have also suggested
that ESA administration to cancer patients is associated
with increased mortality [25,26], however the topic has
remained controversial [27,28]. In renal patients it is not
sure whether it is the need to administer high doses of ESA,
thus ESA resistance, or the high ESA doses themselves that
result in a higher mortality rate. Anemia correction trials in
chronic renal patients associated high hemoglobin targets
and therefore higher ESA doses with mortality [29,30] or
cardiovascular events [31,32]. In our study in HD patients
with Hb level <11 g/dL, mortality rate was also increasing
with increasing ESA doses. Only in patients with the lowest
ESA dose mortality rate did not further decrease, as also
previously published [33]. The patients with a high ESA
dose and adequate Hb response in our study generally had
a higher mortality rate as well, but a dose dependent effect
was not consistently shown. Some other studies reported
no harmful effect of high ESA dose [34-36].
In our cohort of patients ESA resistance was not only
associated with cardiovascular mortality but also with
non-cardiovascular mortality. A remarkable finding since
the hypothesized mechanism through which high ESA
dose would increase mortality, namely elevated arterial
blood pressure, altered endothelial function and
prothrombotic effects [37], would mainly result in car-
diovascular causes of mortality. ESA resistance com-
prises more than just high ESA dose and is linked to
malnutrition, inflammation, low iron stores, hyperpara-
thyroidism, and other co-morbid conditions with in-
creased mortality risk [38-41]. It may therefore be
regarded as an indicator for disease severity, but even
after adjustment for a wide range of these confounders
ESA resistance is still associated with mortality. Thus
the inability to achieve a proper hematopoietic re-
sponse seems to be the best marker of worse progno-
sis. Secondary analyses of anemia correction trials also
confirm this association between ESA resistance and
mortality [12,42], but the causal pathway is not yet
fully understood.
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tation of our results. Despite adjustment for a wide
range of confounders, residual confounding cannot be
excluded. Although our cohort comprised incident in-
stead of prevalent dialysis patients, some potential sur-
vivor bias might be left because only patients that
survived 6 months on dialysis were included in the
present analyses (1474 patients). Our patients were not
incident ESA users and changes in Hb, ESA dose or dia-
lysis modality after baseline were not taken into account.
Information on route of ESA administration, type of
ESA, iron management and iron status besides ferritin
was not available. Further investigation is needed to
explore the role of these factors.
Conclusions
In our cohort of incident dialysis patients, we showed
that ESA resistance, defined by an above median ESA
dose and Hb <11 g/dL, was associated with increased
mortality in HD and PD patients. This strengthens the
need to investigate and treat causes of ESA resistance
not only in HD, but also in PD patients. Additional stu-
dies are needed to disentangle the effect of ESA resis-
tance, high ESA doses and Hb level on mortality.
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